上腺素与多巴胺治疗新生儿感染性休克:一项随机对照试验
Mohammad Yusuf Ali Mazhari1, Mayank Priyadarshi1, Poonam Singh1
1Department of Neonatology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
The Journal of pediatrics
|April 19, 2025
概括
上腺素 (NE) 和多巴胺 (DA) 在治疗新生儿感染性休克时表现出类似的有效性. 虽然这两种药物都类似地扭转了冲击,但多巴胺与更高的心率和更低的脑氧和有关.
科学领域:
- 新生儿科学 新生儿科学
- 儿科重症监护 儿科重症监护
- 药理学 药理学 是一个学科.
背景情况:
- 新生儿的败血性休克是一个关键的情况,需要迅速的血管活性支持.
- 上腺素和多巴胺是常用的第一线药物,但它们在新生儿中的比较有效性仍在争论中.
- 耐液性败血性休克需要积极的管理来改善结果.
研究的目的:
- 为了比较上腺素与多巴胺作为新生儿初始血管活性剂的疗效,新生儿患有耐液性败血性休克.
- 评估二次结果,包括冲击逆转的时间,需要额外的药物,以及各种生理参数.
- 在这个脆弱人群中评估这两种药物的安全性.
主要方法:
- 一个随机对照试验,涉及80名新生儿,患有耐液性败血性休克.
- 参与者被分配给接受诺拉上腺素 (n=41) 或多巴胺 (n=39) 作为第一线治疗.
- 血管活性药物剂量在定义范围内启动和升级,首要结果是30分钟后的冲击逆转.
主要成果:
- 在诺拉上腺素和多巴胺组之间,在30分钟内实现冲击逆转的新生儿比例没有显著差异 (32%对46%,P=19).
- 冲击逆转的时间,需要额外的血管活性药物和类固醇,乳酸水平和死亡率在各组之间是可比的.
- 与上腺素组相比,多巴胺组在24小时内表现出更高的心率,脑组织氧和度降低,pH值降低.
结论:
- 当作为一线药物使用时,上腺素和多巴胺在逆转新生儿的败血性休克方面表现出相似的疗效.
- 虽然这两种药物都有效,但多巴胺使用与心跳动和大脑氧化率下降等不良影响有关.
- 可能需要进一步的研究,以优化新生儿败血性休克中血管活性剂的选择和定位.
相关概念视频
Adrenergic Agonists: Therapeutic Uses
750
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
750
Adrenergic Agonists: Therapeutic Classification
751
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
751
Adrenergic Agonists: Direct-Acting Agents
1.4K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.4K
Adrenergic Neurons: Neurotransmission
3.5K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
3.5K
Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K


